Overview
Equipoise is a testosterone ester used in hormone replacement and performance protocols. It has a half-life of ~14 days (336 hours). It is tracked in Milligram with one-compartment pharmacokinetic modeling for accurate level predictions.
With a half-life of ~14 days (336 hours), Equipoise supports less frequent dosing schedules. Administered via IM injection, it has a bioavailability of approximately 95% via its primary route.
Half-life approximately 14 days. Slow absorption — approximately 4–6 weeks to reach steady-state plasma levels. One-compartment model.
Mechanism of Action
Equipoise's pharmacological activity involves the following key pathways:
Androgen Receptor Binding
Equipoise binds to androgen receptors in skeletal muscle and other tissues, initiating transcription of androgen-responsive genes involved in protein synthesis and nitrogen retention.
Aromatization
Equipoise is subject to aromatase enzyme conversion, producing estrogenic metabolites. The rate of conversion varies with dose and individual enzyme activity.
Ester Hydrolysis
After injection, the ester bond is cleaved by esterase enzymes, releasing free testosterone into circulation. The ester length determines the rate of release and thus the half-life.
Dosing Protocols
The following protocols represent commonly observed dosing patterns. These are observational summaries, not recommendations.
Dose
100 mg/week
Route
Intramuscular
Frequency
Every 10-14 days
Duration
8-16 weeks
Dose
500 mg/week
Route
Intramuscular
Frequency
Every 10-14 days
Duration
8-16 weeks
Frequently Asked Questions
What is Equipoise (Boldenone Undecylenate) and what was it originally developed for?
Equipoise is the brand name for Boldenone Undecylenate, an injectable anabolic androgenic steroid originally developed for veterinary use – most notably in horses, which is the origin of the 'Equi-' prefix. The undecylenate ester gives it one of the longest half-lives of any injectable anabolic steroid at approximately 14 days (336 hours), meaning it builds up and clears very slowly. It was later repurposed in human use and became popular in bodybuilding and physique sports for its association with steady lean muscle gains, increased vascularity, and appetite stimulation without the degree of water retention seen with testosterone.
How does Equipoise aromatize compared to testosterone?
Equipoise aromatizes to estrogen at a notably lower rate than testosterone – commonly cited at approximately half the aromatization rate of testosterone. This means users generally observe significantly less estrogenic water retention and a 'drier' appearance compared to equivalent doses of testosterone. However, at high doses and over the extended cycle lengths commonly associated with EQ, estrogen accumulation can still occur. Some users also note that Boldenone can convert to a potent estrogen metabolite (boldenone 17-beta) under specific enzymatic conditions, though this is considered less significant than testosterone's aromatization in most user reports.
Why does Equipoise require such long cycle lengths?
Equipoise's undecylenate ester has a half-life of approximately 14 days – one of the longest of any injectable compound. By the 5-half-life rule, steady-state plasma levels are not reached until approximately 70 days (~10 weeks) of consistent dosing. Running a cycle shorter than 14 – 16 weeks means a significant portion of the cycle is spent in the build-up phase rather than at stable, effective levels. Most experienced users report cycles of 16 – 20 weeks to allow adequate time at true steady state. This extended duration is both a defining characteristic and a practical commitment of the compound.
Does Equipoise increase red blood cell production and why does that matter?
Equipoise is commonly associated with a pronounced increase in red blood cell (RBC) production – an erythropoietic effect. Users frequently report elevated hematocrit and hemoglobin levels, which can contribute to increased muscular endurance, vascularity, and the characteristic 'vascular' look the compound is known for. However, significantly elevated hematocrit (above approximately 52 – 54%) is also associated with increased blood viscosity, and this is one of the primary bloodwork markers monitored by users on EQ cycles. Regular blood donation or therapeutic phlebotomy is a commonly reported management strategy when hematocrit rises into concerning ranges.
What is the commonly reported appetite increase on Equipoise?
Increased appetite is one of the most consistently reported subjective effects of Equipoise and is considered a distinguishing characteristic compared to many other injectable steroids. Many users specifically select EQ for this property when attempting to maintain a caloric surplus for lean muscle building. The mechanism is not fully elucidated but is thought to involve central and peripheral androgen receptor activity influencing hunger signalling. Users in a caloric deficit sometimes find the appetite stimulation an unwanted effect; it is most commonly valued in gaining or recomposition contexts.
How long does Equipoise stay detectable after a cycle?
Due to its very long undecylenate ester, Equipoise has one of the longest detection windows of any injectable steroid – commonly cited at up to 4 – 5 months after the last injection under standard anti-doping urine testing. Some reports suggest detection is possible for up to 12 months under highly sensitive testing methods. This extended window is a direct consequence of the 14-day half-life and the subsequent slow release of the parent compound from the injection depot over many weeks. Users subject to sports drug testing should account for this extended clearance timeline.